NCT00647673View on ClinicalTrials.gov

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2006

Study Completion Date

February 28, 2006

Conditions
Healthy
Interventions
DRUG

Verapamil HCL Extended-Release Capsules 300 mg

300mg, single dose fasting

DRUG

Verelan® PM Extended-Release Capsules 300 mg

300mg, single dose fasting

Trial Locations (1)

58104

PRACS Institute, Ltd., Fargo

Sponsors
All Listed Sponsors
lead

Mylan Pharmaceuticals Inc

INDUSTRY

NCT00647673 - Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg | Biotech Hunter | Biotech Hunter